Contemporary short‐term peri‐operative outcomes of open primary retroperitoneal lymph node dissection
- 3 September 2024
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 134 (6) , 953-959
Abstract
Objectives: To provide current peri‐operative outcomes and short‐term complication rates for open primary retroperitoneal lymph node dissection (RPLND), with analysis of risk factors for complications. Patients and Methods: Using the Indiana University Testicular Cancer database, we performed a retrospective analysis of all patients who underwent open primary RPLND over the study period (2018–2021). The primary outcomes of interest were the preoperative profile of patients undergoing surgery, complication rates, and identification of risk factors associated with complications. We used chi‐squared, Fisher's exact and unpaired t ‐tests in our analyses. Results: A total of 165 patients were identified. The median body mass index (BMI) was 28.6 kg/m 2 . Patients most often had clinical stage IIA (39%) or IIB testicular cancer (36%). The median estimated blood loss was 150 mL, with no transfusions required. Higher BMI was noted in patients that sustained any complication vs those with normal recovery (34.95 vs 28 kg/m 2 ; P = 0.0042). The median length of hospital stay was 3 days. The overall complication rate was low (8.48%), with two major postoperative complications, including one case of chylous ascites (0.6%), and no deaths in the 30‐day period. The study was limited by its retrospective design and short‐term follow‐up. Conclusions: We found that open primary RPLND has an acceptable morbidity profile, even among a predominantly overweight cohort. Low blood loss, short hospital stay, minimal chylous ascites risk, and rare major postoperative complications should be the benchmark for retroperitoneal lymph node dissection.Keywords
This publication has 29 references indexed in Scilit:
- Robotic retroperitoneal lymph node dissection for testicular cancer at a national referral centreBJUI Compass, 2022
- Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional CohortEuropean Urology Focus, 2021
- Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and PneumoperitoneumEuropean Urology, 2019
- Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomesWorld Journal of Urology, 2019
- Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular CancerEuropean Urology, 2017
- Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the TechniqueEuropean Urology, 2016
- Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of RecurrenceEuropean Urology, 2010
- Short-Term Morbidity of Primary Retroperitoneal Lymph Node Dissection in a Contemporary Group of PatientsJournal of Urology, 2007
- Clinical stage B non-seminomatous germ cell testis cancer: The Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissectionEuropean Journal of Cancer, 1995
- Stage II nonseminomatous germ-cell testicular tumors ? the Indiana experience and risk-benefit analysisWorld Journal of Urology, 1994